CRAFA
PEPTIDE & COMPOUND ANALYSIS

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-1119
Issued: 2026-10-05

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

PRODUCT IDENTIFICATION

PRODUCT	SKU / INTERNAL CODE	PRESENTATION
Cagrilintide	CRF-CAGRILINTIDE	Lyophilised powder, 5 mg vial
BATCH NUMBER	SAMPLE RECEIVED	PRODUCTION DATE
LOT-2610-119	2026-09-28	2026-09-25
ANALYSIS DATE	EXPIRY / RETEST DATE	MOLECULAR FORMULA
2026-10-03	2028-10-03	C194H312N54O59S2
MOLECULAR WEIGHT (G/MOL)	CAS	
4409.0	1415456-99-3	

Research Use Only (RUO). Not for human or veterinary use, consumption, or clinical diagnosis.

ANALYTICAL METHOD — HPLC

INSTRUMENT	COLUMN	COLUMN TEMPERATURE
Waters ACQUITY UPLC	C4 2.1×100mm	60°C
MOBILE PHASE A	MOBILE PHASE B	FLOW RATE
0.1% TFA H2O	0.1% TFA ACN	0.3 mL/min
DETECTION WAVELENGTH	INJECTION VOLUME	SAMPLE CONCENTRATION
214 nm	5 µL	0.5 mg/mL
DILUENT	RETENTION TIME (MAIN PEAK)	
50:50 ACN:H2O	12.1 min	

Recorded methods: HPLC-UV (214 nm) · LC-MS/MS · ICP-MS · LAL · Sterility

RESULTS

Test	Acceptance Criteria	Result	Verdict
HPLC Purity (% area)	≥98.0%	99.7%	PASS
Identity (LC-MS)	4410.0 ±2%	Obs: 4410.3 [M+H]+	PASS

Test	Acceptance Criteria	Result	Verdict
Quantity found	95.0–105.0%	4.98 mg (99.6%)	PASS
Endotoxin	<1.0 EU/mg	<0.5 EU/mg	PASS
Heavy metals	<10 ppm	All <LOQ	PASS

Detected Impurities

No impurity data recorded.

FINAL BATCH RESULT

PASS — Conforms to specifications

No chromatogram data recorded.

Analyst notes: Full Elite panel. Sterility negative across 14-day incubation.

crafa

CRAFA